RxDoctor Payments Data

Christa Young

Family · Asheboro, NCNPI 1518688092

Payments from drug & device makers

$7,812in general payments, 2019–2025

Across 483 payments — averaging $16.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$907
  • Lilly USA, LLC$800
  • AbbVie$629
  • Pfizer$619
  • AstraZeneca$570
  • Otsuka America Pharmaceutical, Inc.$548
  • plus $4K from 35 others

What the payments were for

  • Consulting fees$250%
  • Food & beverage$7,787100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,812 in reported general payments places this provider in the 95th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$78,808
Medicare patients
229
Services billed
900

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide19$28,241
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$15,772
FarxigaDapagliflozin Propanediol21$15,378
EliquisApixaban26$10,505
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$9,817
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog14$9,273
JardianceEmpagliflozin14$8,269
LinzessLinaclotide11$6,258
Lorazepam173$3,757
Xtampza ErOxycodone Myristate11$3,333
LokelmaSodium Zirconium Cyclosilicate11$3,080
Modafinil12$2,704
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen72$2,188
Lacosamide13$2,047
Levothyroxine Sodium78$1,252

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Lokelma$570$28,27548 claims
Novo NordiskRybelsus$907$28,24119 claims
GSKTrelegy Ellipta$294$15,77216 claims
PfizerEliquis$619$10,50526 claims
Boehringer IngelheimJardiance$189$8,26914 claims
AbbVieLinzess$629$6,25811 claims
Collegium Pharmaceutical, Inc.Xtampza Er$177$3,33311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,522 family providers in North Carolina.

Other family in Asheboro

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →